MedTrace Logo

A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT07065032 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-07-15

No results posted yet for this study

Summary

This study will comprise a randomized, double blind, placebo controlled, multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in subjects with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

ZT002 Injection

Q2W, subcutaneous injection

DRUG

ZT002 Injection

Q2W, subcutaneous injection

DRUG

ZT002 Placebo

Participants will receive the same volume as the study drug in each cohort.

Sponsors & Collaborators

  • Beijing QL Biopharmaceutical Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Yu Cao, PhD · The Affiliated Hospital of Qingdao University

  • Chengqian Li, MD · The Affiliated Hospital of Qingdao University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2024-07-22
Completion
2024-08-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07065032 on ClinicalTrials.gov